Ursodeoxycholic Acid
CAS number:128-13-2
-
Molecular Formula:
C24H40O4
-
Molecular Weight:
392.6g/mol
-
Brief Introduction:
Ursodeoxycholic acid (UDCA) is a bile acid with significant therapeutic potential, as evidenced by its applications in treating neonatal cholestasis, primary biliary cholangitis (PBC), and improving health in periparturient dairy cows. In neonatal cholestasis, UDCA combined with phenobarbital effectively improved liver function and reduced serum bilirubin levels, with a high total effective rate of 94.00% and good safety, showing no serious adverse reactions. For PBC patients, UDCA alone or in combination with alfacalcidol demonstrated efficacy in improving liver function and reducing liver stiffness, with the combination therapy significantly increasing treatment response rates and improving hepatic fibrosis. In dairy cows, UDCA supplementation enhanced milk yield, reduced oxidative stress and inflammation, and positively altered the gut microbiota, contributing to better health and performance during the transition period. These studies collectively highlight UDCA's multifaceted benefits in improving liver function, reducing inflammation, and enhancing overall health in both human and veterinary medicine.
Bile Acids
UDCA is a naturally occurring bile acid, which is a type of steroid acid derived from cholesterol. Bile acids are synthesized in the liver and play a crucial role in the digestion and absorption of fats and fat-soluble vitamins.
Cholane Derivatives
UDCA is a derivative of the cholane family, which is characterized by a steroid nucleus with a side chain at the 17th carbon. The cholane skeleton is common to many bile acids.
Hydroxylated Steroids
UDCA contains hydroxyl groups at specific positions on the steroid nucleus (e.g., 3α, 7β, and 12α positions), which are typical of hydroxylated steroids. These hydroxyl groups contribute to its amphipathic nature, allowing it to interact with both water and lipids.
Secondary Bile Acids
UDCA can be considered a secondary bile acid because it is produced by the modification of primary bile acids (such as chenodeoxycholic acid) by gut microbiota. This conversion occurs through processes like dehydroxylation and deconjugation.
128-13-2 Suppliers
Shanghai Chinese and Western 3D Drug Co.,Ltd.
Shanghai Chinese and Western 3D Drug Co., Ltd. is a Shanghai Pharmaceuticals directly affiliated company. It was formed in June 2010 by the former Shanghai Chinese and Western Pharmaceutical Co., Ltd., which has a century-old history, and Shanghai Sanwei Pharmaceutical Co., Ltd., a large domestic pharmaceutical company. It is the carrier of Shanghai Pharmaceuticals' development of special raw materials and supporting preparations.
Jiangsu Yellow River Pharmaceutical Co., Ltd.
Jiangsu Yellow River Pharmaceutical Co., Ltd. was founded in 1970. Its predecessor was the Jiangsu Provincial Local State-owned Funing County Pharmaceutical Factory (later renamed Yancheng Fourth Pharmaceutical Factory). In 1999, it was acquired by the Yellow River Group to form Jiangsu Yellow River Pharmaceutical Co., Ltd.
Guangzhou Chemical Reagent Factory
With more than 1200 product varieties and over 3000 specifications, Guangzhou Chemical Reagent Factory serves a wide range of sectors including scientific research institutions, inspection and quarantine services, environmental monitoring, biopharmaceuticals, electronics, electroplating, healthcare, aerospace technology, new energy, and more.
